Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/6/10 → 03/12/13 |
Funding
- Celator Pharmaceuticals Incorporated: $15,319.00
Phase IIB, Multicenter, Randomized, Open-Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adult Patients <65 Years Old with AML in First Relapse Following an Initial CR >1 Month Duratio
- Schuster, Michael (PI)
Project: Research